Nathalia Galvão-Coelho
Psychiatric Researcher
Data updated
Papers
Trials
Research Footprint
Nathalia Galvão-Coelho appears in 13 tracked papers (2018–2025), most studied alongside Ayahuasca, DMT and Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).
Frequent co-authors: Fernanda Palhano-Fontes, Draulio Araújo and Daniel Perkins.
Publication Landscape
How the 13 papers Blossom tracks for Nathalia Galvão-Coelho line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Nathalia Galvão-Coelho's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Nathalia Galvão-Coelho publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Nathalia Galvão-Coelho publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Nathalia L. Galvão-Coelho is a psychiatric researcher whose work spans translational animal models, controlled clinical studies and large-scale naturalistic surveys focused on psychedelic compounds—most prominently ayahuasca. Her research portfolio includes preclinical investigations using juvenile non-human primate models of depressive-like behaviour, randomized controlled observations of single-dose ayahuasca effects, and biomarker studies linking antidepressant response to changes in inflammatory mediators and serum brain-derived neurotrophic factor (BDNF).
She has also contributed to epidemiological and qualitative studies that examine patterns of ayahuasca use, context and setting effects on mental health outcomes, and associations with alcohol and other drug use across international samples. In addition to primary empirical work, she has co-authored syntheses and meta-analytic reviews on classic serotonergic psychedelics for mood disorders, helping to integrate clinical, biological and contextual perspectives relevant to therapeutic development and harm–benefit assessment.
Key Impact
Noted for translational and clinical research on ayahuasca and other classic serotonergic psychedelics, particularly their antidepressant effects, biological mechanisms and the role of context in naturalistic use.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Nathalia Galvão-Coelho's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Nathalia Galvão-Coelho is associated with.